Geneticists certify 108 high-confidence Alzheimer’s risk signals

The effort, published open access in Genome Medicine, was designed to address a persistent problem in the field: the quality of genetic association claims varies widely across studies, and many reported signals have never been systematically re-examined against uniform standards.

The committee worked in two phases. Phase 1 established tiered criteria for judging the strength of genetic evidence, testing the framework on 23 nominated loci across different study designs. Phase 2 then applied those criteria to 29 large-scale genome-wide studies published between January 2015 and September 2022, the date of the last literature search. In total, 163 unique loci were tiered according to the new framework, allowing the team to separate robustly supported associations from weaker or unverified claims.

The results were substantial. Phase 1 yielded 17 high-confidence association signals, 12 of which carried specific gene-level support. Phase 2 identified 93 high-confidence single-variant signals and 25 high-confidence variant-set signals. After removing signals that overlapped across evidence classes, the committee arrived at a final catalog of 108 unique high-confidence signals associated with Alzheimer’s disease and related dementias. Each of these associations has now passed a common, systematically applied bar of evidence rather than relying on the thresholds of individual original studies.

Beyond the count itself, the prioritized loci point to biological pathways already central to Alzheimer’s research, including APP processing, microglial immunity, and lipid metabolism. Notably, the adjudication surfaced genes that are not captured by existing community resources such as Agora or Open Targets, suggesting that a structured re-review of published associations can recover targets that standard databases miss. The summarized results have been made publicly browsable at topgenes.niagads.org, hosted through the NIAGADS resource.

The authors position the catalog as a foundation for two downstream goals: functional validation of prioritized genes in laboratory systems, and therapeutic discovery aimed at the pathways the signals highlight. Because the tiering framework was built to be systematic rather than disease-specific in its logic, the committee argues the approach has broad applicability to other complex diseases, where similar variation in association quality complicates target selection. As a resource, the catalog does not by itself establish causal mechanisms or clinical utility; it defines which genetic associations currently meet the highest evidentiary standard, providing a vetted starting list for the experimental work that must follow. The article was published as an open-access paper on 27 October 2026, released early as a citable, peer-reviewed accepted version carrying a permanent DOI.

Subject of Research: Systematic adjudication of genetic associations with Alzheimer's disease and related dementias

Article Title: Comprehensive adjudication identifies 108 high-confidence genetic signals for Alzheimer’s disease and related dementias

Article References: Leung, Y. Y., Marcora, E. M., Naj, A., Patel, T., Sedgwick, K., Katanic, Z., Corces, M. R., Wang, L.-S., Mayeux, R., Goate, A., Farrer, L., Schellenberg, G. D., Kunkle, B., & N. Vardarajan, B. (2026). Comprehensive adjudication identifies 108 high-confidence genetic signals for Alzheimer’s disease and related dementias. Genome Medicine. https://doi.org/10.1186/s13073-026-01802-y

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01802-y

Keywords: Alzheimer's disease, genetics, genome-wide association studies, Gene Verification Committee, ADRD, APP processing, microglial immunity, lipid metabolism, NIAGADS, Genome Medicine, loci adjudication, therapeutic targets